Efficacy, safety and albuminuria‐reducing effect of gemigliptin in <scp>K</scp> orean type 2 diabetes patients with moderate to severe renal impairment: <scp>A</scp> 12‐week, double‐blind randomized study (the <scp>GUARD S</scp> tudy) - Concepedia

Concepedia

Publication | Open Access

Efficacy, safety and albuminuria‐reducing effect of gemigliptin in <scp>K</scp> orean type 2 diabetes patients with moderate to severe renal impairment: <scp>A</scp> 12‐week, double‐blind randomized study (the <scp>GUARD S</scp> tudy)

DOI Full Paper Access

27

Citations

32

References

2016

Year

Sun Ae Yoon, Byoung Geun Han, Sung G. Kim, Sang Youb Han, Young Il Jo, Kyung Hwan Jeong, K.-H. Oh, Hyeong Cheon Park, Sun H. Park, Shin‐Wook Kang,

Diabetes Obesity and Metabolism

Abstract

A 12-week treatment with gemigliptin improved glycaemic control and provided UACR reduction in T2DM patients with moderate to severe RI. Gemigliptin was well tolerated, with no additional risk of hypoglycaemia and change in body weight.

References

	Year	Citations

Page 1